What is the typical Survodutide dosage?

Published protocols describe 0.6–4.8 mg weekly, given subcutaneous. This is context from the literature, not a recommendation: a licensed provider sets the dose.

What are the side effects of Survodutide?

Risks noted for Survodutide include nausea, vomiting, diarrhea, and constipation. Tell your provider about your medications and conditions before starting.

What is the half-life of Survodutide?

The reported half-life is ~5–6 days (limited data). Onset is typically reported at 2–4 weeks for appetite reduction.

How should Survodutide be stored?

Refrigerated (2–8 °C); use within the pharmacy beyond-use date.

GLP-1 · PEPTIDE

What is Survodutide?

Medically reviewed by the G1 Peptides clinical team · Updated October 1, 2026

THE SHORT ANSWER

Survodutide is an investigational once-weekly injectable that activates the glucagon and GLP-1 receptors. It is being studied for obesity and for MASH, a form of fatty liver disease.

Survodutide at a glance

Type: Peptide
Also known as: BI 456906
Mechanism: Dual glucagon / GLP-1 receptor agonist
Status: Phase 3
Half-life: ~5–6 days (limited data)
Route: Subcutaneous
Dosing range in the literature: 0.6–4.8 mg weekly
Onset: 2–4 weeks for appetite reduction
Storage: Refrigerated (2–8 °C); use within the pharmacy beyond-use date

How Survodutide works

GLP-1 activity reduces appetite, while glucagon activity acts on the liver to increase fat breakdown and energy use. The liver effect is the reason it is being studied in MASH.

What Survodutide is studied for

Weight management
MASH / liver fat

A phase 2 trial in MASH showed improvement in liver disease in a large share of participants. Phase 3 trials in obesity and MASH are ongoing.

Being studied for something is not proof that it works. Results in individuals vary.

Survodutide dosing

Published protocols describe 0.6–4.8 mg weekly, once weekly, given subcutaneous. Onset is typically reported at 2–4 weeks for appetite reduction.

These figures are context from the literature, not instructions. A licensed provider sets the dose and schedule for each patient.

Survodutide dosage calculator →

Survodutide side effects and risks

Nausea
Vomiting
Diarrhea
Constipation

Tell your provider about every medication and condition before starting, and report anything unexpected. See peptide side effects and safety and who should not use peptides.

Is Survodutide FDA approved?

Investigational. In phase 3 trials and not approved by the FDA.

Approval and trial status change. This page was last reviewed on October 1, 2026.

Survodutide at G1 Peptides

G1 Peptides does not currently supply Survodutide. A provider can discuss alternatives in a free consultation.

Survodutide questions

What is Survodutide?: Survodutide is an investigational once-weekly injectable that activates the glucagon and GLP-1 receptors. It is being studied for obesity and for MASH, a form of fatty liver disease.
What is Survodutide used for?: Survodutide is studied for weight management and mASH / liver fat. A phase 2 trial in MASH showed improvement in liver disease in a large share of participants. Phase 3 trials in obesity and MASH are ongoing.
How does Survodutide work?: GLP-1 activity reduces appetite, while glucagon activity acts on the liver to increase fat breakdown and energy use. The liver effect is the reason it is being studied in MASH.
Is Survodutide FDA approved?: Investigational. In phase 3 trials and not approved by the FDA.
What is the typical Survodutide dosage?: Published protocols describe 0.6–4.8 mg weekly, given subcutaneous. This is context from the literature, not a recommendation: a licensed provider sets the dose.
What are the side effects of Survodutide?: Risks noted for Survodutide include nausea, vomiting, diarrhea, and constipation. Tell your provider about your medications and conditions before starting.
What is the half-life of Survodutide?: The reported half-life is ~5–6 days (limited data). Onset is typically reported at 2–4 weeks for appetite reduction.
How should Survodutide be stored?: Refrigerated (2–8 °C); use within the pharmacy beyond-use date.

For educational purposes only, and not medical advice. These statements have not been evaluated by the FDA. Nothing on this page is intended to diagnose, treat, cure, or prevent any disease. Use any compound only under the guidance of a licensed provider.